Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
Taiwan · Delayed Price · Currency is TWD 29.80
-0.05 (-0.17%)
Jan 22, 2026, 1:30 PM CST
TPEX:4111 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,361 | 1,165 | 1,061 | 1,143 | 1,022 | 979.36 | Upgrade | |
Revenue Growth (YoY) | 23.28% | 9.86% | -7.19% | 11.81% | 4.38% | -4.26% | Upgrade |
Cost of Revenue | 830.63 | 768.25 | 717.76 | 720.57 | 665.72 | 656.44 | Upgrade |
Gross Profit | 530.33 | 397.18 | 343.1 | 422.51 | 356.58 | 322.92 | Upgrade |
Selling, General & Admin | 320.35 | 280.24 | 260.22 | 248.99 | 218.59 | 229.15 | Upgrade |
Research & Development | 16.75 | 18 | 21.67 | 19.69 | 18.94 | 18.21 | Upgrade |
Operating Expenses | 337.1 | 298.25 | 281.89 | 268.67 | 237.52 | 247.37 | Upgrade |
Operating Income | 193.23 | 98.93 | 61.21 | 153.84 | 119.06 | 75.55 | Upgrade |
Interest Expense | -0.62 | -1.74 | -1.46 | -1.53 | -1.09 | -0.16 | Upgrade |
Interest & Investment Income | 8.74 | 14.58 | 16.64 | 3 | 0.6 | 1.99 | Upgrade |
Currency Exchange Gain (Loss) | -4.38 | 17.08 | -0.43 | 4.72 | -1.76 | -3.25 | Upgrade |
Other Non Operating Income (Expenses) | 11.68 | 11.22 | 11.5 | 7.21 | 8.06 | 7.09 | Upgrade |
EBT Excluding Unusual Items | 208.65 | 140.08 | 87.46 | 167.24 | 124.86 | 81.22 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -5.03 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -1.17 | -2.38 | -0.13 | 0.07 | 0.12 | 0.2 | Upgrade |
Asset Writedown | - | - | - | - | 6.8 | - | Upgrade |
Other Unusual Items | - | - | 0 | - | - | - | Upgrade |
Pretax Income | 207.48 | 137.7 | 87.33 | 162.28 | 131.78 | 81.43 | Upgrade |
Income Tax Expense | 42.13 | 27.07 | 18.66 | -17 | 24.08 | 22.28 | Upgrade |
Earnings From Continuing Operations | 165.35 | 110.63 | 68.67 | 179.28 | 107.7 | 59.14 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -25.28 | -26.95 | - | Upgrade |
Net Income | 165.35 | 110.63 | 68.67 | 154.01 | 80.75 | 59.14 | Upgrade |
Net Income to Common | 165.35 | 110.63 | 68.67 | 154.01 | 80.75 | 59.14 | Upgrade |
Net Income Growth | 131.35% | 61.10% | -55.41% | 90.72% | 36.54% | -18.37% | Upgrade |
Shares Outstanding (Basic) | 60 | 60 | 60 | 60 | 60 | 60 | Upgrade |
Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 60 | 60 | Upgrade |
Shares Change (YoY) | 0.47% | 0.12% | -0.16% | 0.06% | 0.10% | -0.01% | Upgrade |
EPS (Basic) | 2.76 | 1.85 | 1.15 | 2.57 | 1.35 | 0.99 | Upgrade |
EPS (Diluted) | 2.75 | 1.84 | 1.14 | 2.56 | 1.34 | 0.98 | Upgrade |
EPS Growth | 131.97% | 60.83% | -55.37% | 90.77% | 36.85% | -18.89% | Upgrade |
Free Cash Flow | 148.26 | 129.01 | -26.98 | 109.53 | -125.53 | 121.53 | Upgrade |
Free Cash Flow Per Share | 2.46 | 2.15 | -0.45 | 1.82 | -2.09 | 2.02 | Upgrade |
Dividend Per Share | 0.952 | 0.952 | 0.952 | 1.143 | 0.952 | 0.952 | Upgrade |
Dividend Growth | - | - | -16.67% | 20.00% | - | - | Upgrade |
Gross Margin | 38.97% | 34.08% | 32.34% | 36.96% | 34.88% | 32.97% | Upgrade |
Operating Margin | 14.20% | 8.49% | 5.77% | 13.46% | 11.65% | 7.71% | Upgrade |
Profit Margin | 12.15% | 9.49% | 6.47% | 13.47% | 7.90% | 6.04% | Upgrade |
Free Cash Flow Margin | 10.89% | 11.07% | -2.54% | 9.58% | -12.28% | 12.41% | Upgrade |
EBITDA | 259.12 | 165.23 | 123.17 | 219.2 | 190.95 | 152.45 | Upgrade |
EBITDA Margin | 19.04% | 14.18% | 11.61% | 19.18% | 18.68% | 15.57% | Upgrade |
D&A For EBITDA | 65.89 | 66.3 | 61.96 | 65.36 | 71.9 | 76.9 | Upgrade |
EBIT | 193.23 | 98.93 | 61.21 | 153.84 | 119.06 | 75.55 | Upgrade |
EBIT Margin | 14.20% | 8.49% | 5.77% | 13.46% | 11.65% | 7.71% | Upgrade |
Effective Tax Rate | 20.31% | 19.66% | 21.36% | - | 18.27% | 27.37% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.